BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34619371)

  • 1. A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle.
    Feng ZH; Li ZT; Zhang S; Wang JR; Li ZY; Xu MQ; Li H; Zhang SQ; Wang GX; Liao A; Zhang X
    Acta Biomater; 2021 Dec; 136():495-507. PubMed ID: 34619371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
    Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
    J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death.
    Zhang Y; Guo C; Liu L; Xu J; Jiang H; Li D; Lan J; Li J; Yang J; Tu Q; Sun X; Alamgir M; Chen X; Shen G; Zhu J; Tao J
    Theranostics; 2020; 10(24):11197-11214. PubMed ID: 33042278
    [No Abstract]   [Full Text] [Related]  

  • 5. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy.
    Shi Y; Li D; He C; Chen X
    Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
    Li C; Han X
    Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma.
    Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y
    J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
    Liu D; Li K; Gong L; Fu L; Yang D
    Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy.
    Emami F; Banstola A; Vatanara A; Lee S; Kim JO; Jeong JH; Yook S
    Mol Pharm; 2019 Mar; 16(3):1184-1199. PubMed ID: 30698975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
    Dong H; Gao M; Lu L; Gui R; Fu Y
    Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of MHC-I and downregulation of PD-L1 expression by doxorubicin and deferasirox codelivered liposomal nanoparticles for chemoimmunotherapy of melanoma.
    Song P; Han X; Zheng R; Yan J; Wu X; Wang Y; Zhang H
    Int J Pharm; 2022 Aug; 624():122002. PubMed ID: 35817272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
    Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
    Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma.
    Chen Y; Luo X; Liu Y; Zou Y; Yang S; Liu C; Zhao Y
    Int J Nanomedicine; 2022; 17():3989-4008. PubMed ID: 36105615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using anti-PD-L1 antibody conjugated gold nanoshelled poly (Lactic-co-glycolic acid) nanocapsules loaded with doxorubicin: A theranostic agent for ultrasound imaging and photothermal/chemo combination therapy of triple negative breast cancer.
    Jiang H; Zhou Y; Zheng D; Cheng Y; Xiang D; Jiang L; Du J
    J Biomed Mater Res A; 2024 Mar; 112(3):402-420. PubMed ID: 37941485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo.
    Nguyen VD; Min HK; Kim CS; Han J; Park JO; Choi E
    Colloids Surf B Biointerfaces; 2019 Jan; 173():539-548. PubMed ID: 30343218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.